Immunological effectiveness of mass hepatitis B vaccination
- Authors: Shulakova N.I1, Akimkin V.G2,3,4, Kisteneva L.B5
-
Affiliations:
- Medical Prevention Center, Moscow Healthcare Department
- Research Institute of Disinfectology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Welfare
- I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia
- Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Welfare
- Honorary Academician N.F Gamaleya Federal Research Center for Epidemiology and Microbiology, Ministry of Health of Russia
- Issue: No 4 (2016)
- Pages: 33-36
- Section: Articles
- URL: https://journals.eco-vector.com/2226-6976/article/view/278479
- ID: 278479
Cite item
Open Access
Access granted
Abstract
Objective. To evaluate the immunological effectiveness of hepatitis B (HB) vaccination in the population of certain regions of Russia, including those within the Health project. Materials and methods. A total of 803 sera from adults vaccinated against hepatitis B with the Engerix-B vaccine according to the standard immunization schedule (0-1-6 months) were examined in 4 subjects of the Russian Federation (Moscow Region, Sverdlovsk Region, Perm Territory, and Moscow). Blood samples were taken at 3-6 and 7-12 months and 1-2, 3-5, 6-7, and 8-12 years after completing a full HB vaccine series. Hepatitis B markers (HBsAg, anti-HBs, anti-HBcor overall and class IgM) were quantified in the vaccinated by chemiluminescence assay on an automated ARCHITECT immunochemical analyzer using Architect test kits (Abbott Laboratories Diagnostics, USA). The serum concentration of 10 mIU/ml and higher was considered as a seroprotective level of specific antibodies. The results were processed using modern statistical methods. Results. The protective concentrations of specific antibodies were found in the blood of 88.23 ± 8.06% of cases at 3-6 months after completing a full HB vaccine series and persisted in 71.26 ± 4.56% within 8-12 years. At 3-6 months after completion of a full vaccine series, the proportion of individuals with a protective HBV antibody titer in the age groups 20-39 and 40-59 years had no significant differences and accounted for 90.0 ± 10.0% and 89.4 7 ± 7.23%, respectively. At 6-7 years after vaccination, the proportion of the individuals seropositive for HB virus in the age groups 20-39 and 40-59 years decreased to 72.0 ± 5.18 and 71.79 ± 7.21%, respectively. Conclusion. The results obtained from serological monitoring confirmed the high immunological effectiveness of hepatitis B vaccination in the population in some regions of Russia.
Keywords
Full Text
About the authors
N. I Shulakova
Medical Prevention Center, Moscow Healthcare Department
Email: shulakova.msk@mail.ru
Moscow
V. G Akimkin
Research Institute of Disinfectology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Welfare; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia; Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Welfare
Email: vgakimkin@yandex.ru
Moscow
L. B Kisteneva
Honorary Academician N.F Gamaleya Federal Research Center for Epidemiology and Microbiology, Ministry of Health of Russia
Email: lborisovna2007@yandex.ru
Moscow
References
- Fattovich G., Stroffolini T., Zagni I., Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004; 127(5) (Suppl. 1): 35-50.
- Shepard C.W., Simard E.P., Finelli L., Fiore A.E., Bell B.P. Hepatitis B virus infection: epidemiology and vaccination. Epidemiol. Rev. 2006; 28: 112-125.
- Marcellin P. Hepatitis B and hepatitis C in 2009. Liver Int. 2009; 29(1): 1-8.
- Селезнёва Т.С. Современная стратегия вакцинопро-филактики инфекционных заболеваний в мире и на территории Российской Федерации. Федеральный справочник. Здравоохранение России: информационно-аналитическое издание. Т. 11. М.: НП «Центр стратегического партнерства», 2010. 443 с.
- Expanded Programme on Immunization. Global Advisory Group. Part I. Wkl Epidemiol. Rec. 1992; 67: 11-15.
- Пименов H.H., Вдовин А.В., Комарова С.В., Мамонтова Н.А., Чуланов В.П., Покровский В.И. Актуальность и перспективы внедрения в России единого федерального регистра больных вирусными гепатитами В и С. Тер. архив 2013; 85(11): 4-9.
- Государственный доклад «О состоянии санитарно-эпидемиологического благополучия населения в Российской Федерации в 2014 году». М.: Федеральная служба по надзору в сфере защиты прав потребителей и благополучия человека, 2015. 206 с.
- Зверев В.В. Вакцинация против вирусного гепатита В: природа и длительность формируемого иммунитета. Вакцинация. Информ. бюллетень 2001; 3(15): 6-8.
- Бектимиров Т.А. Успехи и проблемы вакцинопрофилактики гепатита В в мире. Вакцинация. Информ. бюллетень 2001; № 3(15): 4-5.
- Бектимиров Т.А., Горбунов М.А., Шалунова Н.В. Результаты регистрационных испытаний вакцины «Эувакс» для профилактики гепатита В. Вакцинация. Информ. бюллетень 1999; (4): 8-9.
- ПенкинаТ.В., Чупыра Т.М., Гурбатова Т.Ю., Мельникова С.В., Васильев А.Ю. Широта распространенности маркеров гепатита В среди медицинского персонала многопрофильного стационара и определение напряженности поствакцинального иммунитета. Мир вирусных гепатитов 2006; (6): 11-17.
- Шахгильдян И.В., Михайлов М.И., Онищенко Г.Г. Парентеральные вирусные гепатиты (эпидемиология, диагностика, профилактика). М.: ГОУ ВУНМЦ МЗ РФ, 2003. 384 с.
Supplementary files
